Osiris Therapeutics, Inc. OSIR today announced that
C. Randal Mills, Ph.D., President and Chief Executive Officer, will host a
conference call to discuss the results of the interim analysis of its
multicenter, randomized, controlled trial evaluating the efficacy and safety
of Grafix® for the treatment of chronic diabetic foot ulcers. The call will be
held tomorrow, August 13, 2013 at 9:00 a.m. ET.
To access the webcast, visit the Investor Relations section of the company's
website at http://investor.osiris.com/events.cfm. Alternatively, callers may
participate in the conference call by dialing (877) 303-6133 (U.S.
participants) or (970) 315-0493 (international participants).
An archive of the webcast will be available approximately two hours after the
completion of the call. To access the archived webcast, visit the Investor
Relations section of the company's website at
http://investor.osiris.com/events.cfm.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in